Investment Rating - The report maintains a "Strong Buy" rating for the company [5] Core Views - The company achieved a revenue of 2.066 billion yuan in 2024, representing a year-on-year growth of 25.18%, and a net profit of 673 million yuan, up 26.08% year-on-year [1] - The company has entered the atrial fibrillation treatment market with the approval of new products such as AForcePlusTM catheter and PulstamperTM catheter [2] - The financial performance remains robust, with a comprehensive gross margin increase of 1.05 percentage points to 72.31% in 2024 [3] Financial Performance - In 2024, the company reported a comprehensive gross margin of 72.31%, with a net profit margin of 31.86% [3] - The first quarter of 2025 saw a revenue of 564 million yuan, a 23.93% increase year-on-year, and a net profit of 183 million yuan, up 30.69% year-on-year [1] - The company forecasts revenues of 2.691 billion yuan, 3.475 billion yuan, and 4.553 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 900 million yuan, 1.172 billion yuan, and 1.535 billion yuan [3][10] Business Segments - The electrophysiology segment generated 440 million yuan in revenue in 2024, a year-on-year increase of 19.73%, with over 15,000 three-dimensional electrophysiology surgeries performed [2] - The vascular intervention segment reported revenues of 1.054 billion yuan for coronary products and 351 million yuan for peripheral products, with significant increases in new admissions [2] Valuation Metrics - The company is projected to have a PE ratio of 45, 34, and 26 for the years 2025, 2026, and 2027, respectively [3][10] - The current stock price is 413.0 yuan, with a market capitalization of 40.1 billion yuan [5]